Pesquisa assistência farmacêutica no SUSgasto em medicamentos judicializados de estados e municípios participantes (2019-2023)
Vieira, Fabiola Sulpino; Chaves, Elton da Silva; Costa, Karen Sarmento; Bernarde, Heber Dobis; Bernardes, Liliane Cristina Gonçalves; Cavalcanti, Filipe Matheus Silva; Pereira, Blenda Leite Saturnino
O documento é disponibilizado pela fonte de origem, que mantém a versão integral e as condições de uso.
Resumo
This text aims to analyze the expenditures on litigated pharmaceuticals by the municipalities and states participating in the Unified Health System (SUS)’ Pharmaceutical Service Research and to discuss the process of health judicialization in this system. Issues related to pharmaceuticals judicialization are included in the research questionnaire, which was conducted by Ipea in partnership with the National Council of Municipal Health Departments (Conasems) and National Council of Health Secretaries (Conass) in 2024. In this study, data were collected from municipalities, the Federal District, and states regarding the management and financing of this area between 2019 and 2023. The data on expenditures for litigated pharmaceuticals were processed to eliminate outliers, and the analysis was conducted by government sphere and geographical region, using basic descriptive statistics to summarize the main findings. A high prevalence of judicial demands for pharmaceuticals was found among municipalities (58.7%) and states (100%), as well as the provision of pharmaceutical products not registered with the National Health Surveillance Agency (Anvisa) and off-label, and the implementation of administrative procedures for dispensing pharmaceuticals not incorporated into the SUS. In 2023, on average, expenditure on litigated pharmaceuticals consumed 8.4% and 32.9% of the total pharmaceutical expenditure in the municipalities and states partici¬pating in the study, respectively. The results highlight the widespread judicialization in SUS, with significant impacts on the budgets of subnational entities, particularly the states, and the potential to exacerbate inequalities in access to pharmaceuticals and health inequities in Brazil.
Ficha do documento
- Tipo
- Estudo
- Ano
- 2025
- Instituição
- Instituto de Pesquisa Econômica Aplicada (Ipea)
- Fonte
- Repositório do Ipea
- Idioma
- Português
- Acesso
- Acesso aberto
- Identificador
- oai:repositorio.ipea.gov.br:11058/17238
- Licença
- Licença Comum
- Abrangência
- Brasil; 2019-2023
Conteúdos relacionados
- EstudoPesquisa Assistência Farmacêutica no SUSInstituto de Pesquisa Econômica Aplicada (Ipea) · 2025
- RelatórioAssistência farmacêutica no SUSInstituto de Pesquisa Econômica Aplicada (Ipea) · 2023
- EstudoEvolução do gasto com medicamentos do Sistema Único de Saúde no período de 2010 a 2016Instituto de Pesquisa Econômica Aplicada (Ipea) · 2018
- EstudoIndutores do gasto direto do Ministério da Saúde em medicamentos (2010-2019)Instituto de Pesquisa Econômica Aplicada (Ipea) · 2021
